Solid Biosciences (SLDB) Total Liabilities (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Total Liabilities data on file, last reported at $48.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 1.38% year-over-year to $48.8 million; the trailing twelve-month figure through Mar 2026 stood at $48.8 million (down 1.38% YoY), and the FY2025 full-year result was $52.5 million, up 2.17% from the prior year.
• Total Liabilities eased to $48.8 million in Q1 2026, from $52.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $56.0 million in Q3 2025 to a low of $22.0 million in Q1 2022.
• A 5-year average of $44.3 million and a median of $45.8 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 31.7% in 2022 and surged 107.76% in 2023, its largest moves.
• Tracing SLDB's Total Liabilities over 5 years: stood at $48.6 million in 2022, then slipped by 20.85% to $38.5 million in 2023, then surged by 33.69% to $51.4 million in 2024, then gained by 2.17% to $52.5 million in 2025, then slipped by 7.17% to $48.8 million in 2026.
• Business Quant data shows SLDB's Total Liabilities at $48.8 million in Q1 2026, $52.5 million in Q4 2025, and $56.0 million in Q3 2025.